Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Market Intelligence

Set Alert for Market Intelligence

Danish Design: How Danes Aim To Grow Their Life Sciences Output

Denmark has generated high growth rates from its life science industry. The country's government, industry and academic centers are increasingly working together to keep up that momentum.

Denmark Companies

Ten Strategies For Success In Antibody-Drug Conjugate Development

The future looks rosy after a slow start for antibody-drug conjugates. But what are the best tactics to capture a slice of the growing opportunity?

Research and Development Strategies Platform Technologies

AstraZeneca’s Outlicensing Tactics Make It Top Dealmaker

Datamonitor report highlights big pharma’s licensing trends from last five years, and finds UK firm top on numbers of deals, but Merck & Co put up most money.

Deals Commercial

Interview: AstraZeneca’s Pangalos On Landmark DAPA-HF Results

AstraZeneca’s head of R&D spoke to Scrip about the outstanding results for dapagliflozin in heart failure regardless of diabetes status.

Cardiovascular Clinical Trials

European Life Science Companies Are Now Being ‘Properly Funded’

In the first half of 2019, life science companies raised $469m through series A rounds in Europe – a solid start to the year compared with the $686m companies raised in 2018 overall. Experts says this "rude health" should continue for the next two to three years, at least.

Europe Financing

Big Pharma Nibbles As Turkey’s Localization Policy Yields Limited Results

The Turkish Government’s carrot-and-stick “localization” policy has started to yield results with some multinational pharma companies including GSK and Sanofi disclosing joint production ventures with local companies, but these ventures have been limited by difficult economic conditions and worsening investment environment, and the fixed euro rate.

Turkey Manufacturing

AZ's Dapagliflozin Impresses In Topline Phase III Heart Failure Study

AstraZeneca’s SGLT2 inhibitor has grabbed attention for its potential role in chronic heart failure patients, with or without type 2 diabetes, following initial results from the DAPA-HF study.

 

Clinical Trials Market Intelligence

Janssen's Imbruvica Leads CLL Market Expansion In Europe

Imbruvica is keeping ahead of potential competitors in Europe by expanding its use in patients with chronic lymphocytic leukemia and Waldenström’s macroglobulinemia.

 

Market Intelligence Cancer

Top 10 Drugs: Biologic Blockbusters And The Biosimilar Threat

INFOGRAPHIC: maturing cancer and autoimmune biologics still top the league for global revenues, but biosimilars are snapping at their heels.

 

Biologics Commercial
See All
UsernamePublicRestriction

Register